Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Cadila Pharmaceuticals Limited
WARNING LETTER
•Cadila Pharmaceuticals Limited•March 28, 2014

Cadila Pharmaceuticals Limited – FDA Warning Letter, Mar 28, 2014

Record Details

This FDA Warning Letter, dated February 25, 2015, to Cadila Pharmaceuticals Limited, details significant deviations from current Good Manufacturing Practice (CGMP) for Active Pharmaceutical Ingredients (APIs) observed during a March 24-28, 2014 inspection of their Ankleshwar, India facility. These deviations render their APIs adulterated under 21 U.S.C. 351(a)(2)(B).

Key violations include: 1. **Inadequate Complaint Investigations:** Failure to fully investigate complaints and extend investigations to affected batches since 2011. Examples cited include an unpleasant odor complaint for (b)(4) API in September 2011, where corrective actions were not implemented before closing the investigation, and an August 2012 complaint for odor and out-of-specification (OOS) unknown impurity in (b)(4) API, where supporting data was not retained or showed discrepancies, and the quality unit failed to recognize the OOS prior to release. 2. **Quality Unit Deficiencies:** The quality unit failed to ensure APIs complied with CGMP and met specifications. For instance, (b)(4) API batch (b)(4) was released with an unknown peak in the residual solvents chromatogram, later identified as contamination, which analysts and supervisors failed to notice or evaluate. 3. **Data Integrity Issues:** Failure to prevent unauthorized access

Company
Cadila Pharmaceuticals Limited
Inspection date
March 28, 2014
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas J. Cosgrove
View Company Profile

ID · e632d2bc-00bb-46bd-af88-c34895517e74

Violation Codes4
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)21 U.S.C. 356C(a)(1)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cadila Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.